We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+2.69%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$8.16B
AUM Growth
+$296M
Cap. Flow
-$1.61B
Cap. Flow %
-19.71%
Top 10 Hldgs %
74.41%
Holding
114
New
7
Increased
22
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$80.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$65.5M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$58.8M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$48.9M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$35.8M

Top Sells

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$84.5M
2
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$37.3M
3
HALO icon
Halozyme
HALO
+$24.8M
4
GILD icon
Gilead Sciences
GILD
+$23.4M
5
QCOR
QUESTCOR PHARMA INC
QCOR
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 44.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
51
Xencor
XNCR
$2.07B
$6.3M 0.08%
542,363
– –
INSM icon
52
Insmed
INSM
$27.5B
$6.08M 0.07%
304,050
-250,000
-45% -$3.7M
NVAX icon
53
Novavax
NVAX
$1.47B
$5.65M 0.07%
61,168
– –
CYTR
54
DELISTED
CytRx Corp
CYTR
$5.64M 0.07%
225,000
– –
CPRX
55
DELISTED
Catalyst Pharmaceutical
CPRX
$5.62M 0.07%
2,223,053
+1,653,200
+290% +$3.53M
RXDX
56
DELISTED
Ignyta, Inc.
RXDX
$5.19M 0.06%
571,000
– –
AMBI
57
DELISTED
Ambit Biosciences Corp
AMBI
$5.17M 0.06%
747,954
– –
BDSI
58
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$5.08M 0.06%
421,005
– –
STML
59
DELISTED
Stemline Therapeutics, Inc.
STML
$4.97M 0.06%
338,671
– –
ZGNX
60
DELISTED
Zogenix, Inc.
ZGNX
$4.72M 0.06%
293,800
– –
ACGN
61
DELISTED
Aceragen Inc
ACGN
$4.68M 0.06%
11,873
– –
LGND icon
62
Ligand Pharmaceuticals
LGND
$5.71B
$4.57M 0.06%
117,660
– –
RARE icon
63
Ultragenyx Pharmaceutical
RARE
$2.55B
$4.49M 0.06%
100,000
– –
KPTI icon
64
Karyopharm Therapeutics
KPTI
$44.5M
$4.38M 0.05%
6,273
+2,333
+59% +$1.09M
GALT icon
65
Galectin Therapeutics
GALT
$371M
$4.14M 0.05%
300,000
-200,000
-40% -$2.49M
CNCE
66
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$4.03M 0.05%
+398,800
New +$3.85M
AKTX
67
Akari Therapeutics
AKTX
$15.3M
$3.71M 0.05%
84
– –
IONS icon
68
Ionis Pharmaceuticals
IONS
$9.93B
$3.32M 0.04%
96,303
– –
ACHN
69
DELISTED
Achillion Pharmaceuticals
ACHN
$3.32M 0.04%
438,337
– –
ENTA icon
70
Enanta Pharmaceuticals
ENTA
$392M
$3.25M 0.04%
75,357
-5,600
-7% -$214K
VXRT
71
DELISTED
Vaxart
VXRT
$3.15M 0.04%
100,628
– –
ALDR
72
DELISTED
Alder Biopharmaceuticals
ALDR
$3.08M 0.04%
+153,350
New +$2.16M
LPCN icon
73
Lipocine
LPCN
$17.2M
$3.05M 0.04%
+29,412
New +$3.52M
TBRA
74
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$2.72M 0.03%
44,444
– –
MDWD icon
75
MediWound
MDWD
$171M
$2.56M 0.03%
+32,143
New +$2.62M
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2014 Portfolio in Review

As of Q2 2014, Julian Baker held 114 positions worth $8.16B, up 3.8% from $7.87B the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Julian Baker withdrew a net $1.61B in Q2 2014, closing 9 positions and reducing 9 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $84.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 48% a quarter earlier.

Against the trend, Julian Baker opened a new position in Aravive, Inc. Common Stock worth $34.9M.

  • Julian Baker's largest Q2 2014 buy was Aravive, Inc. Common Stock: 207,648 shares worth $34.9M.
  • Julian Baker added most to PHARMACYCLICS INC in Q2 2014, an estimated $80.1M increase.
  • Julian Baker's biggest Q2 2014 reduction was Halozyme, cutting an estimated $24.8M.
  • Julian Baker fully exited Intercept Pharmaceuticals, Inc. in Q2 2014, selling an estimated $84.5M.
  • Julian Baker's ten largest holdings make up 74% of its $8.16B portfolio in Q2 2014.
  • Julian Baker opened 7 new positions and closed 9 in Q2 2014.
  • Julian Baker's portfolio value rose 3.8% quarter-over-quarter to $8.16B.

Based on Baker Bros. Advisors's 13F filing for Q2 2014, filed 14 Aug 2014.